SV2009003160A - Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap) - Google Patents
Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)Info
- Publication number
- SV2009003160A SV2009003160A SV2009003160A SV2009003160A SV2009003160A SV 2009003160 A SV2009003160 A SV 2009003160A SV 2009003160 A SV2009003160 A SV 2009003160A SV 2009003160 A SV2009003160 A SV 2009003160A SV 2009003160 A SV2009003160 A SV 2009003160A
- Authority
- SV
- El Salvador
- Prior art keywords
- smac
- iap
- peptidomimetics
- inhibitors
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA (I); O SALES FARMACÉUTICAMENTE ACEPTABLES DEL MISMO, Y AL USO DE ESTOS COMPUESTOS PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS, TALES COMO CÁNCER, EN MAMÍFEROS: (VER FORMULA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83500006P | 2006-08-02 | 2006-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2009003160A true SV2009003160A (es) | 2010-04-13 |
Family
ID=38686647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2009003160A SV2009003160A (es) | 2006-08-02 | 2009-02-02 | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap) |
Country Status (41)
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080242658A1 (en) | 2004-04-07 | 2008-10-02 | Mark G Palermo | Inhibitors of Iap |
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| EP1836201B2 (en) | 2004-12-20 | 2013-09-04 | Genentech, Inc. | Pyrrolidine inhibitors of iap |
| BRPI0607988A2 (pt) | 2005-02-25 | 2009-10-27 | Tetralogic Pharmaceuticals | composto, composição farmacêutica, e método para induzir apoptose em uma célula |
| WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| JP2009512719A (ja) | 2005-10-25 | 2009-03-26 | アエゲラ セラピューティクス インコーポレイテッド | Ｉａｐｂｉｒドメイン結合化合物 |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| SG171682A1 (en) | 2006-05-16 | 2011-06-29 | Aegera Therapeutics Inc | Iap bir domain binding compounds |
| WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| AR063943A1 (es) | 2006-07-24 | 2009-03-04 | Tetralogic Pharmaceuticals Cor | Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer. |
| CL2007002166A1 (es) | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
| US20100316573A1 (en) * | 2006-10-19 | 2010-12-16 | Larry Alexander Gaither | Organic Compounds |
| US8492429B2 (en) * | 2006-11-28 | 2013-07-23 | Novartis Ag | Combination of IAP inhibitors and FLT3 inhibitors |
| EA200900691A1 (ru) * | 2006-11-28 | 2009-12-30 | Новартис Аг | Применение ингибиторов iap для лечения острого миелоидного лейкоза |
| JP2010513561A (ja) * | 2006-12-19 | 2010-04-30 | ジェネンテック， インコーポレイテッド | Ｉａｐのイミダゾピリジンインヒビター |
| CA2683392A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| WO2009140447A1 (en) * | 2008-05-16 | 2009-11-19 | Novartis Ag | Immunomodulation by iap inhibitors |
| EP2318395A4 (en) | 2008-08-02 | 2011-10-26 | Genentech Inc | IPA INHIBITORS |
| US8841067B2 (en) | 2009-01-09 | 2014-09-23 | Dana-Farber Cancer Institute, Inc. | NOL3 is a predictor of patient outcome |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
| WO2011019782A1 (en) * | 2009-08-11 | 2011-02-17 | Novartis Ag | Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists |
| BR112012003118A2 (pt) * | 2009-08-12 | 2016-02-23 | Novartis Ag | formulações orais sólidas e formas cristalinas de um inibidor de proteína apoptose |
| MX340870B (es) | 2010-02-12 | 2016-07-27 | Pharmascience Inc | Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus. |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| KR101560227B1 (ko) * | 2010-08-31 | 2015-10-14 | 한미사이언스 주식회사 | 세포사멸 유도 활성을 갖는 퀴놀린 또는 퀴나졸린 유도체 |
| WO2012052758A1 (en) | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| EP2731942B1 (en) | 2011-07-13 | 2015-09-23 | Novartis AG | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
| US20140243276A1 (en) | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| JP6267193B2 (ja) * | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| KR20140011773A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 이중 저해 활성을 갖는 헤테로고리 유도체 |
| CA2907912A1 (en) | 2013-05-01 | 2014-11-06 | F. Hoffmann-La Roche Ag | C-linked heterocycloalkyl substituted pyrimidines and their uses |
| KR20200108904A (ko) | 2013-06-25 | 2020-09-21 | 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 | 세포내 감염의 치료 방법 |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
| JP2017535528A (ja) | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| AR103894A1 (es) | 2015-03-10 | 2017-06-14 | Aduro Biotech Inc | Composiciones y métodos para activar la señalización dependiente del estimulador del gen interferón |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| EA201891093A1 (ru) | 2015-11-03 | 2018-10-31 | Янссен Байотек, Инк. | Антитела, специфически связывающие pd-1, и их применение |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| US10781205B2 (en) | 2016-04-20 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN106496213B (zh) * | 2016-09-30 | 2019-08-20 | 东南大学 | Lcl161前药及其制备方法和应用 |
| JP6899993B2 (ja) * | 2016-10-04 | 2021-07-07 | 国立医薬品食品衛生研究所長 | 複素環化合物 |
| BR112019016737A2 (pt) | 2017-03-31 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Terapia anticâncer combinada |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN108484640B (zh) * | 2018-05-22 | 2020-09-15 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的细胞凋亡蛋白抑制剂 |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| JP7515175B2 (ja) | 2018-07-31 | 2024-07-12 | ファイメクス株式会社 | 複素環化合物 |
| JP7504106B2 (ja) | 2019-01-17 | 2024-06-21 | デビオファーム・インターナショナル・エス・アー | がんの処置のための組合せ物 |
| TWI894135B (zh) | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| AU2020256220A1 (en) | 2019-04-04 | 2021-09-16 | Dana-Farber Cancer Institute, Inc. | CDK2/5 degraders and uses thereof |
| WO2020236825A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2021020585A1 (ja) | 2019-07-31 | 2021-02-04 | ファイメクス株式会社 | 複素環化合物 |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| PH12022550721A1 (en) | 2019-09-25 | 2024-05-13 | Debiopharm Int Sa | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| EP4093394A1 (en) | 2020-01-20 | 2022-11-30 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US12171795B2 (en) | 2020-06-03 | 2024-12-24 | Boehringer Ingelheim International Gmbh | Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein |
| CA3202759A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2022112942A2 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| KR20250027281A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| WO2024189481A1 (en) | 2023-03-10 | 2024-09-19 | Novartis Ag | Panras inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714880A1 (de) | 1977-04-02 | 1978-10-26 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| JPS59141547A (ja) | 1983-02-01 | 1984-08-14 | Eisai Co Ltd | 鎮痛作用を有する新規ペプタイドおよび製法 |
| FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
| US5559209A (en) | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| US6472172B1 (en) | 1998-07-31 | 2002-10-29 | Schering Aktiengesellschaft | DNA encoding a novel human inhibitor-of-apoptosis protein |
| AU2001265008A1 (en) | 2000-05-23 | 2001-12-03 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| US20020160975A1 (en) | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
| US20030157522A1 (en) | 2001-11-09 | 2003-08-21 | Alain Boudreault | Methods and reagents for peptide-BIR interaction screens |
| JP4541882B2 (ja) | 2002-07-02 | 2010-09-08 | ノバルティス アーゲー | Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤 |
| DE60324964D1 (de) | 2002-07-15 | 2009-01-08 | Univ Princeton | Iap-bindende verbindungen |
| US20040171554A1 (en) | 2003-02-07 | 2004-09-02 | Genentech, Inc. | Compositions and methods for enhancing apoptosis |
| WO2005049853A2 (en) | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Compositions and methods for screening pro-apoptotic compounds |
| CA2553871A1 (en) * | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| SE527038C2 (sv) * | 2004-02-26 | 2005-12-13 | Ingenjoers N Per Oskar Persson | Kassett och apparat för vätskefrysning |
| WO2005084317A2 (en) | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| US20080242658A1 (en) | 2004-04-07 | 2008-10-02 | Mark G Palermo | Inhibitors of Iap |
| EP1778718B1 (en) | 2004-07-02 | 2014-10-08 | Genentech, Inc. | Inhibitors of iap |
| EP1836201B2 (en) | 2004-12-20 | 2013-09-04 | Genentech, Inc. | Pyrrolidine inhibitors of iap |
| US20060218632A1 (en) * | 2005-03-28 | 2006-09-28 | Cisco Technology, Inc.; | Method and system for installing premise equipment |
| AU2007307763A1 (en) * | 2006-10-12 | 2008-04-17 | Novartis Ag | Pyrrolydine derivatives as IAP inhibitors |
| RU2009125620A (ru) * | 2006-12-07 | 2011-01-20 | Новартис АГ (CH) | Органические соединения |
-
2007
- 2007-07-26 PE PE2011000113A patent/PE20110220A1/es not_active Application Discontinuation
- 2007-07-26 PE PE2011000111A patent/PE20110217A1/es not_active Application Discontinuation
- 2007-07-26 PE PE2011000112A patent/PE20110218A1/es not_active Application Discontinuation
- 2007-07-26 PE PE2011000114A patent/PE20110224A1/es active IP Right Grant
- 2007-07-26 PE PE2007000978A patent/PE20080951A1/es active IP Right Grant
- 2007-07-31 CN CN2007800329568A patent/CN101511860B/zh active Active
- 2007-07-31 EP EP07813569A patent/EP2051990B1/en active Active
- 2007-07-31 MX MX2009001212A patent/MX2009001212A/es active IP Right Grant
- 2007-07-31 KR KR1020097004264A patent/KR101087878B1/ko active Active
- 2007-07-31 JP JP2009523001A patent/JP4875749B2/ja active Active
- 2007-07-31 EA EA201401247A patent/EA201401247A1/ru unknown
- 2007-07-31 EP EP12184700A patent/EP2537850A1/en not_active Withdrawn
- 2007-07-31 PT PT78135696T patent/PT2051990E/pt unknown
- 2007-07-31 PL PL07813569T patent/PL2051990T3/pl unknown
- 2007-07-31 US US12/376,057 patent/US8552003B2/en active Active
- 2007-07-31 EP EP12184747.9A patent/EP2537846B1/en active Active
- 2007-07-31 GE GEAP200711084A patent/GEP20115251B/en unknown
- 2007-07-31 ME MEP-2009-19A patent/ME00585B/me unknown
- 2007-07-31 AU AU2007281230A patent/AU2007281230B2/en active Active
- 2007-07-31 MY MYPI20090334 patent/MY150460A/en unknown
- 2007-07-31 UA UAA200900768A patent/UA95485C2/uk unknown
- 2007-07-31 AR ARP070103375A patent/AR062159A1/es not_active Application Discontinuation
- 2007-07-31 KR KR1020117002855A patent/KR101245945B1/ko active Active
- 2007-07-31 ES ES12184747.9T patent/ES2559042T3/es active Active
- 2007-07-31 EA EA200900227A patent/EA021671B1/ru not_active IP Right Cessation
- 2007-07-31 CA CA2658525A patent/CA2658525C/en active Active
- 2007-07-31 BR BRPI0714803A patent/BRPI0714803B8/pt active IP Right Grant
- 2007-07-31 ES ES07813569T patent/ES2405947T3/es active Active
- 2007-07-31 NZ NZ574393A patent/NZ574393A/en not_active IP Right Cessation
- 2007-07-31 WO PCT/US2007/074790 patent/WO2008016893A1/en not_active Ceased
- 2007-07-31 HR HRP20130373TT patent/HRP20130373T1/hr unknown
- 2007-07-31 DK DK07813569.6T patent/DK2051990T3/da active
- 2007-07-31 CN CN201110446951.8A patent/CN102558165B/zh active Active
- 2007-07-31 SI SI200731218T patent/SI2051990T1/sl unknown
- 2007-08-01 TW TW096128289A patent/TWI408133B/zh not_active IP Right Cessation
- 2007-08-01 CL CL200702234A patent/CL2007002234A1/es unknown
- 2007-08-02 PA PA20078740901A patent/PA8740901A1/es unknown
- 2007-08-02 JO JO2007318A patent/JO2848B1/en active
-
2009
- 2009-01-16 CR CR10567A patent/CR10567A/es unknown
- 2009-01-16 ZA ZA2009/00371A patent/ZA200900371B/en unknown
- 2009-01-19 IL IL196596A patent/IL196596A/en active IP Right Grant
- 2009-01-22 NI NI200900008A patent/NI200900008A/es unknown
- 2009-01-22 NI NI2009000081A patent/NI200900081A/es unknown
- 2009-01-29 CU CU20090017A patent/CU23866B1/es active IP Right Grant
- 2009-01-30 TN TN2009000034A patent/TN2009000034A1/fr unknown
- 2009-01-30 HN HN2009000214A patent/HN2009000214A/es unknown
- 2009-01-30 GT GT200900019A patent/GT200900019A/es unknown
- 2009-02-02 SV SV2009003160A patent/SV2009003160A/es active IP Right Grant
- 2009-02-17 MA MA31648A patent/MA30652B1/fr unknown
- 2009-02-25 NO NO20090878A patent/NO342230B1/no not_active IP Right Cessation
- 2009-02-26 SM SM200900013T patent/SMP200900013B/it unknown
-
2011
- 2011-02-02 CU CU2011000027A patent/CU24004B1/es active IP Right Grant
-
2012
- 2012-09-07 US US13/606,676 patent/US8546336B2/en active Active
-
2013
- 2013-04-16 DO DO2013000084A patent/DOP2013000084A/es unknown
- 2013-08-29 US US14/013,666 patent/US20140004101A1/en not_active Abandoned
- 2013-10-23 GT GT200900019AK patent/GT200900019AA/es unknown
-
2014
- 2014-02-20 IL IL231079A patent/IL231079A/en active IP Right Grant
- 2014-12-03 CR CR20140555A patent/CR20140555A/es unknown
-
2015
- 2015-01-22 IL IL236883A patent/IL236883A0/en unknown
-
2017
- 2017-12-04 AR ARP170103398A patent/AR110313A2/es unknown
-
2018
- 2018-09-17 AR ARP180102641A patent/AR112816A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009003160A (es) | Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap) | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| PA8852901A1 (es) | Inhibidores de proteina cinasa | |
| PA8841901A1 (es) | Compuestos orgánicos | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| NI201400026A (es) | 3 - pirimidin - 4 - il - oxazolidin - 2 - onas como inhibidores de la idh mutante. | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| GT201300180A (es) | "compuesto de imidazo (4,5-c) quinolin-2-ona y su uso como inhibidor dual de cinasa pi3/mtor" | |
| MX2012013206A (es) | Inhibidores de quinasa biciclica fusionada. | |
| UY32052A (es) | 5-aminopirazoles sustituidos y uso de los mismos | |
| CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
| SV2011003784A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
| CL2011001850A1 (es) | Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. | |
| CU20110025A7 (es) | Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap) | |
| CU20110024A7 (es) | Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap) | |
| CU20110026A7 (es) | Peptidomiméticos de smac útiles como inhibidores de proteínas de apoptosis (iap) | |
| UY30514A1 (es) | Compuestos organicos | |
| NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa | |
| DOP2009000012A (es) | (s)-n-((s)-1-ciclohexil-2-{(s)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metilamino- propionamida, un pectidomimético de smac útil como un inhibidor de iap, activo en la inhibición de la proliferación de células cancerosas | |
| CL2011000647A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de enlace de la proteina smac al iap; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades proliferativas. (divisional de la solicitud 2234-2007). | |
| CL2011001401A1 (es) | Compuesto derivado de morfina-6-glucuronido; composicion farmaceutica que lo comprende; uso del compuesto en el tratamiento o prevencion del dolor. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant |